Similar articles

• Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century.

  Kweder SL. Kweder SL. Birth Defects Res A Clin Mol Teratol. 2008 Sep;82(9):605-9. doi: 10.1002/bdra.20500. Birth Defects Res A Clin Mol Teratol. 2008. PMID: 18704917 No abstract available.
• Marketing off-label uses to physicians: FDA's draft (mis)guidance.

  Gass A, Wilson J. Gass A, et al. Am J Bioeth. 2008 Mar;8(3):1-3. doi: 10.1080/15265160802116624. Am J Bioeth. 2008. PMID: 18570084 No abstract available.
• Medication use in pregnancy and the pregnancy and lactation labeling rule.

  Sahin L, Nallani SC, Tassinari MS. Sahin L, et al. Clin Pharmacol Ther. 2016 Jul;100(1):23-5. doi: 10.1002/cpt.380. Epub 2016 May 9. Clin Pharmacol Ther. 2016. PMID: 27082701
• The Food and Drug Administration's regulation of drug labeling, advertising, and promotion: looking back and looking ahead.

  Hayes TA. Hayes TA. Clin Pharmacol Ther. 1998 Jun;63(6):607-16. doi: 10.1016/S0009-9236(98)90083-2. Clin Pharmacol Ther. 1998. PMID: 9663174 Review. No abstract available.
• Psychotropic drug labeling: regulatory, pharmaceutical industry, and clinical issues and perspectives. A pharmaceutical industry perspective on drug labeling.

  Robinson DS. Robinson DS. Psychopharmacol Bull. 1994;30(1):23-5. Psychopharmacol Bull. 1994. PMID: 7972625 Review. No abstract available.